MINNEAPOLIS, Sept. 11 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that an unprecedented number of scientific presentations and symposia will focus on ATS Medical products at the upcoming European Association for Cardio-Thoracic Surgeons (EACTS) meeting. The EACTS is a key gathering of cardiovascular surgeons from around the world and is being held in Lisbon, Portugal from September 13-17, 2008.
Professor Thierry Carrel's presentation at the meeting's Techno College on September 13th is entitled "The ATS Enable Valve: Implantation Techniques and Clinical Results". The ATS 3f Enable(R) Aortic Bioprosthesis incorporates the ATS 3f(R) Aortic Bioprosthesis on a Nitinol self-expanding frame which eliminates the need for traditional suturing. Valuable cardiopulmonary bypass and aortic cross clamp time is reduced while providing surgeons and patients with a minimally invasive alternative to traditional open chest procedures. Also at the Techno College, Dr. Mark Slaughter will present "New Surface Treatment of Mechanical Heart Valves", a report on the novel ATS Forcefield(TM) technology which is intended to modify the surface/platelet interaction and adhesion activity with common biomaterials.
The ATS Medical booth exhibition will spotlight several products including the ATS 3f(R) Aortic Bioprosthesis and the new ATS CryoMaze(TM) Clamp. Based on the precept that 'Form Follows Function', the ATS 3f(R) Aortic Bioprosthesis is a revolutionary stentless pericardial aortic tissue valve that operates unlike any other valve. Like a native aortic valve that functions as a tubular structure whose sides collapse in response to pressure, the proprietary tubular valve design of the ATS 3f Aortic Bioprosthesis reproduces the functional characteristics of a native aortic valve, resulting in more normal distribution of stress on the valve leaflets and laminar, non-turbulent trans-prosthetic flow that is indistinguishable from flow across the normal valve. With more than six years of clinical experience to date confirming excellent safety and efficacy, the combination of normal blood flow dynamics and improved stress distribution offered by the ATS 3f Aortic Bioprosthesis provides surgeons and patients a potentially more durable and physiologic solution to aortic valve replacement. The ATS 3f Aortic Bioprosthesis will be the focus of an EACTS Satellite Symposium on September 16th entitled, "The ATS 3f(R) Revolution" that will be moderated by Dr. James Cox, ATS Medical Director.
The ATS CryoMaze Clamp is the only ablation clamp that offers visible transmurality and allows for safe and effective concomitant ablation in coronary artery bypass graft and aortic procedures using a single device and energy source. The entire ATS CryoMaze product line will be the center of discussions at the ATS Medical Symposium on September 15th entitled "Frontiers In Cryoablation Symposium: The Rationale for Lesion Patterns and Cryosurgery." Ablation therapy is expected to be a key growth driver for the company in 2009.
The ATS Open Pivot(R) Mechanical Heart Valves will be highlighted during an in-booth presentation entitled "Anticoagulation of Mechanical Valves and Our ATS Open Pivot Experience" by Professor Guido Van Nooten on Tuesday, September 16th at 10:45 AM.
The ATS Simulus(R) Semi Rigid Annuloplasty Ring, the newest addition to the company's expanding line of mitral valve repair prosthetics, will also be introduced to the European marketplace.
Michael Dale, President and CEO of ATS Medical commented, "Each year we look forward to the EACTS as one of the premier events within the cardiac surgeon community that we serve. This year is particularly exciting. After more than five years of investment and partnerships towards advancing the standard of cardiac surgery, the number of new and genuinely innovative product offerings from ATS in both our heart valve therapies and surgical ablation of cardiac arrhythmias businesses have never been greater. With new clinical updates on our novel Enable sutureless valve, our Forcefield technology, and our Open Pivot mechanical heart valve, we believe that ATS Medical will be of keen interest to many attendees during this year's EACTS meeting."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.
|SOURCE ATS Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved